MUBI's 'The Substance' and Focus Features' 'Conclave' are specialized movies that both see the wisdom of opening wide.

The Alliance for Pediatric Device Innovation (APDI), a nonprofit consortium led by Children's National Hospital and funded through the Food and Drug Administration (FDA), announces today the ...

16 Chelsea Lauren/Shutterstock Demi Moore, Margaret Qualley and Dennis Quaid are bringing the scares with their new film, The Substance. Written and directed by Coralie Forgeat, the horror film ...

“To me, this is the most exciting time of my life.” Moore stars in a new horror film "The Substance," which follows a former A-list celebrity as she tries a black market drug that temporarily ...

Demi Moore reflected on her experience filming The Substance — which nabbed the Best Screenplay distinction at its Cannes premiere earlier this year — calling the body horror pic an ...

Verify your moisture analyzer’s performance with SmartCal™, a unique routine testing substance. SmartCal verifies the performance of your moisture analyzer in a 10-minute test, which is ...

Demi Moore joins TODAY to talk about her role in the new movie “The Substance” that follows a former A-lister being fired from her TV show and coming across a mysterious new drug. She also ...

The Food and Drug Administration expanded the approval of Kisqali, a drug for metastatic breast cancer, to also treat patients with earlier stages of the disease.

With less than two months until Election Day, VP Kamala Harris and Donald Trump are both talking about the economy. But while Harris talks about actual policy, Trump is serving up a heaping ...

I know that total abstinence from substance use is what’s right for me, and I’m now committed to following this path. But this leaves me unsure how to count my time sober. It’s incredibly ...

The Food and Drug Administration expanded the approval of Kisqali, a drug for metastatic breast cancer, to also treat patients with earlier stages of the disease, drugmaker Novartis said Tuesday.

Analyst Thomas Shrader from BTIG maintained a Buy rating on Inmune Bio (INMB – Research Report) and keeping the price target at $21.00.